Overview
Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Samuraciclib (CT7001): A Comprehensive Profile of a Novel CDK7 Inhibitor in Oncology
II. Introduction to Samuraciclib (CT7001)
Overview and Identification
Samuraciclib, also designated CT7001 and ICEC0942, is an investigational small molecule drug candidate currently undergoing clinical evaluation.1 It possesses the Chemical Abstracts Service (CAS) number 1805833-75-3 and the DrugBank identifier DB16061.5 Originally discovered at Imperial College UK, Samuraciclib is being developed by Carrick Therapeutics, an oncology-focused biopharmaceutical company dedicated to discovering and developing highly differentiated therapies.2
Drug Class and Rationale for Targeting CDK7
Samuraciclib functions as a selective, orally available inhibitor of Cyclin-Dependent Kinase 7 (CDK7).1 CDK7 represents a compelling target in oncology due to its multifaceted roles in fundamental cellular processes frequently dysregulated in cancer.1 Firstly, CDK7 is a critical regulator of transcription, particularly for genes involved in oncogenesis and cell survival.1 Secondly, it plays a pivotal role in controlling cell cycle progression.1 Thirdly, CDK7 activity has been implicated in the development of resistance to established cancer therapies, notably anti-hormone treatments in breast and prostate cancers.1 Furthermore, elevated levels of CDK7 have been observed in various cancer types and often correlate with clinical outcomes, suggesting a heightened dependency of tumor cells on CDK7 activity compared to normal tissues.31 Therefore, inhibiting CDK7 offers a promising therapeutic strategy to simultaneously disrupt these key cancer-driving pathways.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2023/11/09 | Phase 1 | Active, not recruiting | |||
2023/07/27 | Phase 1 | Active, not recruiting | |||
2023/07/27 | Phase 2 | Active, not recruiting | |||
2021/03/17 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.